Journal
TRENDS IN MICROBIOLOGY
Volume 23, Issue 4, Pages 204-211Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.tim.2014.12.007
Keywords
HIV-1; broadly neutralizing antibodies; superinfection; viral evolution; immunotypes; vaccine
Categories
Funding
- CAPRISA
- National Institute of Allergy and Infectious Diseases (NIAID) Center for HIV/AIDS Vaccine Immunology (CHAVI) [AI067854]
- Center for AIDS Vaccine Discovery (CAVD) of the Bill and Melinda Gates Foundation
- South African HIV/AIDS Research and Innovation Platform of the South African Department of Science and Technology
- HIVRAD NIH [AI088610]
- South African Medical Research Council
- NIAID, NIH, US Department of Health and Human Services [U19 AI51794]
- Wellcome Trust [089933/Z/09/Z]
- Wellcome Trust [089933/Z/09/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
The development of a preventative HIV-1 vaccine remains a global public health priority. This will likely require the elicitation of broadly neutralizing antibodies (bNAbs) able to block infection by diverse viral strains from across the world. Understanding the pathway to neutralization breadth in HIV-1 infected humans will provide insights into how bNAb lineages arise, a process that probably involves a combination of host and viral factors. Here, we focus on the role of viral characteristics and evolution in shaping bNAbs during HIV-1 infection, and describe how these findings may be translated into novel vaccine strategies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available